

National Board of Examinations

Question Paper Name :	DrNB Medical Oncology Paper1
Subject Name :	DrNB Medical Oncology Paper1
Creation Date :	2025-01-17 20:02:59
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB Medical Oncology Paper1

Group Number :	1
Group Id :	3271872844
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

DrNB Medical Oncology Paper1

Section Id :	3271872847
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872851
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718736444 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Role of epigenetics in cancer. [4]
- b) Epigenetic editing. [3]
- c) HDAC inhibitors. [3]

Question Number : 2 Question Id : 32718736445 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) RECIST1.1(Response criteria). [4]
- b) FLIPI SCORE. [3]
- c) KELIM SCORE. [3]

Question Number : 3 Question Id : 32718736446 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) What is antibody drug conjugate (ADC)? [4]
- b) Trastuzumab deruxtican (TDxD). [3]
- c) Enumerate ADCs in hematological malignancies. [3]

Question Number : 4 Question Id : 32718736447 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Somatic mutations in cancer. [5]
- b) Key toxicities of CDK4/6 inhibitors commonly used in breast cancer. [3]
- c) Hallmark of cancer. [2]

Question Number : 5 Question Id : 32718736448 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Role of NGS in prostate cancer. [3]
- b) Flow cytometric parameters in CLL. [4]
- c) Cytogenetics in solid malignancies. [3]

Question Number : 6 Question Id : 32718736449 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Survival benefit of dose dense chemotherapy in breast cancer. [4]
- b) Norton Simon hypothesis. [3]
- c) Goldie Coldmann hypothesis. [3]

Question Number : 7 Question Id : 32718736450 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Proton Beam therapy. [4]
- b) Stereotactic body radiation therapy (SBRT). [3.5]
- c) 5 Radiosensitising agents in oncology. [2.5]

Question Number : 8 Question Id : 32718736451 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) PRRT in cancer. [5]
- b) FAPI - PET. [5]

Question Number : 9 Question Id : 32718736452 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Kaplan-Meier survival curve. [4]
- b) Platform Trial. [3]
- c) Basket Trial. [3]

Question Number : 10 Question Id : 32718736453 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Key toxicities of immune checkpoint inhibitors. [5]
- b) Discuss IO AND CTLA combination therapy in oncology. [5]